Malaria, unlike some other pathogens, cannot be transmitted vertically (from mosquito to offspring). So every mosquito starts without an infection and then needs to get infected. For the human malarias, this can only happen by biting an infected human. A completely efficacious vaccine could theoretically whipe out malaria. Of course this does depend on vaccine effectiveness and coverage. Since many individuals in a population can infect mosquitoes, one would need to vaccinate a very large fraction of the total population. In some settings >99% to achieve elimination.
Hi Teun and Isaie! Thanks for doing this AMA.
My question is regarding the promise of targetting different points of infection for prevention and therapy. What I mean is, is there a particular point within the parasite's life-cycle (i.e. its sporogonic cycle (while it's developing in the mosquito), exo-erythrocytic cycle (the human life cycle) or erythrocytic cycle (where matured and awaiting further re-vectorisation by the mosquito)) during which there is the most promise in treating or even eradicating the disease? Also, you mention the development of gametocytes in Dutch volunteers. Now, I have seen a fair number of flyers for Malaria clinical trials around my university and have always been curious if there was any potential danger of infection in such a trial if the control of the pathogenic development fails?
Big_Fil_Preetza
Great question. The best point to break the cycle by vaccination is determined by i) where parasite burden is lowest and, ii) where genetic diversity is lowest. The sexual stage is a promising stage in this respect since many tens of millions of asexual parasites circulate in the bloodstream of an infected host whilst at most several hundreds of sexual stage parasites are ingested by blood feeding mosquitoes. In addition, there is very limited genetic variation in gametocyte proteins, making it a very promising target to develop vaccines or neutralizing antibodies against. Do bioinformatics play a role in your research or the analysis of the gathered data? I'd really like to know if you have interacted with bioinformatics and maby you can tell me how it comes handy in your research.
Thanks

Swagmatic1
bioinformatics becomes increasingly important in our work. We recently published a purely bioinformatics paper that aimed to understand what proteins and what transcripts are specific for gametocytes (http://www.nature.com/articles/s41598-017-18840-7), the parasite stage that we induced in our recent eLife paper. This information is essential to understand biology, develop diagnostics and potentially new interventions. Bioinformatics is becoming crucial in all biology research, malaria is no exception! Thank you very much for doing this AMA, I have two questions for you as a non-specialist.
(1) I would like to know whether you have any thoughts on why it has taken this long for research on malaria to finally pick up some steam, especially considering the fact that it has been a problem for such a great number of people for such a long time (e.g. Europeans in their expeditions to, and conquests of, the 'non-Western' world, as well as those who were 'discovered' to be living in that world; or soldiers fighting on tropical fronts in the two world wars).
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(2) In the eLife paper you very briefly mention that malaria is a contributor to ongoing poverty in affected countries. It is an interesting point to raise, and I realize that this particular paper was not the right place to discuss it at length. I was therefore wondering if you could elaborate a little bit more on it here. Also, do you have any rough ideas on how the complete (or virtual) elimination of malaria may affect developing economies in the future?
JimTonic
Regarding the second question, malaria is estimated to 'cost' Africa approximately 30 billion USD annually. This is the total cost, including deaths, loss of working days, treatment costs etc. In this way reducing the burden of diseases like malaria (and tb and hiv and neglected tropical diseases) is a great way of contributing to economic development.
regarding 1). malaria is a tricky pathogen. Highly complex and in this sense it is not surprising that it is hard to find a solution for it. It is also rather unlikely that there will be a magic bullet that solves the malaria problem on its own. In recent years, there has been great momentum for malaria control and research. This is not due to one factor but the involvement of the Bill & Melinda Gates Foundation is certainly a very positive contributor here. Not only because of financial investments but also in the sense that highly ambitious targets are set.
How do you see malaria control and prevention changing in the next ten years? What's the most dramatic/innovative/important change that's happened in the last ten years? How do national policies and international/ngo groups like PAHO/WHO affect outcomes for individuals and communities? How could they be more effective?
FauxmingAtTheMouth
The last decade has been a great success for control. Not due to particularly novel interventions but because of widescale deployment of effective drugs and vector (=mosuqito) control. The challenge for the coming years will be to move beyond what we achieved so far (reducing burden by half since 2000!) and maintain the gains that are threatened by the development and spread of resistance against both drugs and insecticides.
New drugs and new insecticides are highly needed. One difficult to predict new intervention is the use of malaria-resistant mosquitoes. That holds great promise but also great challenges ahead. The deployment of the first partially efficacious vaccine (mosquirix) in the coming years is also something to look out for. The efficacy is modest at present but it could save many lives. Many tools that we have are actually not properly deployed. This article https://doi.org/10.7554/eLife.09672 is a great example of just how difficult it is to reach very high coverage with the highly efficacious nets that form a cornerstone of the recent gains in malaria control.
Funding is definitely a major issue. To sustain gains an investment of 5 billion USD/year may be required. Even if we were to eradicate malaria, this amount is needed for several years to ensure malaria is truly gone and there is no resurgence.
At the same time, malaria is a tremendously impressive parasite. Flexible in its appearance in humans in mosquitoes, ingenious in escaping human immunity and utilizing the mosquito to maximize its spread. It is no surprise that human malaria parasites have been on the planet pretty much as long as humans exist. The rapid development of parasite resistance against many antimalarial drugs also demonstrates the challenge we are up against. A PhD candidate of mine compared it to the Red Queen from Alice in Wonderland. We need to run to keep up with the parasite and move twice as fast to really gain ground! Hi and thanks for joining us today! 1. What are your thoughts about the claim of health risks in India regarding the release of mosquitoes bearing the "alien bacteria", Wolbachia?
2. Any word on the RTS,S pilot? Anything on the horizon as a potential replacement?
3. Has the situation with the C580Y mutant worsened?
4. Thoughts on the Naled spraying controversy in Florida?
PHealthy 1) I would need to know more about these claims. 2) RTS,S is the only current vaccine that is piloted for implementation. Some other vaccines are under development and may soon enter larger trials. A great overview of timelines is given on http://www.malariavaccine.org/malaria-and-vaccines/malariavaccine-roadmap (download at the right side of the screen) 3) great question. This is a real fear. For many years it was hard to see the impact of artemisinin resistance but now it is considered by some to be a global concern. I tend to agree. True failure rates of antimalarial drugs are rising. So far, it seems largely contained to the SE Asia Greater Mekong Subregion but if it spreads to the highly endemic regions in Africa, a disaster is looming. On the other hand, the last World Malaria Report of the World Health Organization indicated that the positive trend is currently not continuing. There appears to be a flattening of the curve and perhaps even an increase in disease and deaths again in most recent years. Perhaps the low hanging fruits in malaria control have been picked and an increased investment is needed in maximizing the impact of currently available tools (nets, antimalarials, diagnostics, insecticides); and on top of that novel tools are needed to move forward. Our presented controlled human infection -transmission model may prove to be a highly relevant model to test such novel interventions. 
